I acknowledge that the information on this site is for non-US customers only. The site may contain information that is not approved for your country.

Skip to content

For investors
Customer support
Webstore
Document portal

Diagnostic areas
Products
Services
Resources
About us

Contact us

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Post-transplantation
Devyser HLA Loss
One Lambda Devyser Accept cfDNA
One Lambda Devyser Chimerism NGS

Thalassemia
Devyser Thalassemia NGS
Devyser Thalassemia v2

Hereditary cancer
Devyser BRCA NGS
Devyser HBOC NGS
Devyser BRCA PALB2 NGS
Devyser LynchFAP

Fetal RHD screening NIPT
Devyser RHD

Transfusion medicine
Devyser Genomic Blood Typing

Cystic fibrosis
Devyser CFTR
Devyser CFTR Core
Devyser CFTR 68
Devyser CFTR Italia

Cardiovascular diseases
Devyser Thrombophilia
Devyser FH NGS
Devyser HFE
Devyser CVD

Male infertility
Devyser AZF Extension
Devyser AZF v2

Rapid aneuploidy analysis
Devyser Compact
Devyser Complete
Devyser Extend M1
Devyser Resolution 13
Devyser Resolution 18
Devyser Resolution 21
Devyser Resolution XY

Software
Advyser Solid organs
Advyser Chimerism
Amplicon Suite

Cybergene ChromoQuant®
Prenatal diagnostics
Pregnancy loss diagnostics
Male infertility diagnostics

Accessories
560 sizer orange
DEV-5 Dye set
Devyser Index plate A
Devyser Index plate LB-A
Devyser library clean
Devyser Index Plate LB-192

Devyser Genomic Laboratories

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products

Post-transplantation
Thalassemia
- Devyser Thalassemia NGS
- Devyser Thalassemia v2
Hereditary cancer
Fetal RHD screening NIPT
- Devyser RHD
Transfusion medicine
- Devyser Genomic Blood Typing
Cystic fibrosis
Cardiovascular diseases
Male infertility
- Devyser AZF Extension
- Devyser AZF v2
Rapid aneuploidy analysis
Software
Cybergene ChromoQuant®
Accessories

Services

Devyser Genomic Laboratories

Resources

Events & webinars
IVDR
Knowledge hub
Whitepapers
Devyser blog
Frequently asked questions (FAQs)
Calculator for chimerism
Sequence coverage calculator

About us

Our company
Investors
Distributors
News and press
Career
Sustainability
Contact us

For investors
Customer support
Webstore
Document portal

The Devyser blog

Fetal RHD screening NIPT | May 19, 2026

Noninvasive fetal RHD testing is emerging as a standard of care: insights from a global survey

Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and newborn (HDFN) and occurs due to incompatibility between an RhD-negative mother and an RhD-positive...

Find out more

Filter

All articles

A workflow the team trusts: Several years of routine CFTR testing in a reproductive genetics lab in Germany

For many laboratories, CFTR testing is not an occasional add-on. It is part of a routine,...

Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing

Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...

Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market

Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...

Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...

Devyser wins Norwegian tender for Devyser CFTR at Oslo University Hospital

Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...

Devyser secures a four-year tender in France for Devyser Compact

Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...

Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada

Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...

Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test

Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...

Devyser advances U.S. clinical strategy with first patient enrolled in Devyser Accept cfDNA study

Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...

Devyser CFTR achieves IVDR compliance, strengthening clinical confidence in cystic fibrosis diagnostics

Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...

Partnering for progress: A decade of trust in Devyser CFTR

With the IVDR transition approaching, European clinical laboratories are preparing for changes that...

Smarter prophylaxis: How RHD testing protects patients and resources

The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...

1 2 3 4 5 >

Diagnostic areas

Post-transplantation
Oncology
Hematology
Reproductive health
Cystic fibrosis
Cardiovascular diseases

Products and services

Kits and reagents
Our services

Resources

Events & webinars
Knowledge hub
Whitepapers
Devyser blog
Calculator for Chimerism
Sequence coverage calculator
IFUs and certificates

About us

Our company
Contact us
Distributors
News and press
Career
Whistleblowing policy
Sustainability

Investors

Press releases
Reports

© Devyser 2026

Privacy policy | Legal terms | About cookies